91 filings
424B5
ASLN
ASLAN Pharmaceuticals Ltd
11 Dec 20
Prospectus supplement for primary offering
4:19pm
6-K
ASLN
ASLAN Pharmaceuticals Ltd
11 Dec 20
Current report (foreign)
4:11pm
6-K
ASLN
ASLAN Pharmaceuticals Ltd
10 Dec 20
Current report (foreign)
6:22am
6-K/A
ASLN
ASLAN Pharmaceuticals Ltd
13 Nov 20
Aslan Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
6:03am
6-K
ASLN
ASLAN Pharmaceuticals Ltd
9 Nov 20
Aslan Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
9:00am
424B5
14aw1sqx18cw6hnf80j
9 Oct 20
Prospectus supplement for primary offering
5:03pm
6-K
mq1gh0
9 Oct 20
Current report (foreign)
4:03pm
6-K
x76qk
22 Sep 20
Aslan Pharmaceuticals Completes Enrolment In Second Cohort and Opens New Sites In Us and Australia In ASLAN004 Atopic Dermatitis Study
12:00am
6-K
gly sd76q7
17 Sep 20
Current report (foreign)
5:02pm
F-6EF
k0f539 1mib9uxj04gzs
4 Sep 20
Automatic registration for ADRs (foreign)
5:01pm
6-K
61uh9qkd
4 Sep 20
Current report (foreign)
10:14am
6-K
pxskjir6k
24 Aug 20
Aslan Pharmaceuticals Resumes Recruitment of New Patients into ASLAN004 Study
9:25am
6-K
ozmki02uqy5
3 Aug 20
Aslan Pharmaceuticals Appoints Kenneth Kobayashi, MD, As Chief Medical Officer
6:24am
6-K
cj0u d2s9x7i
17 Jul 20
Aslan Pharmaceuticals Announces the Move of Its Primary Listing to Nasdaq and Delisting from Taipei Exchange
6:03am
6-K
jki9 qfx9gx5zu
13 Jul 20
Aslan Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
12:30pm
6-K
b7y96q 9z
15 Jun 20
Current report (foreign)
6:04am
6-K
yjszvl nequ
9 Jun 20
Current report (foreign)
4:31pm
6-K
c648 o6xhfwedop95c
11 May 20
Aslan Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
9:37pm
6-K
xk0l065tjvt6j4cbmg6w
5 May 20
Current report (foreign)
6:02am